INTRODUCTION
Phospholipids are important components of all mammalian cells, and perform a number of biological functions, including the following: 1) form lipid bilayers that provide the structural integrity necessary for protein function, and 2) serve as precursors for a variety of lipid second messengers. Deregulated lipid metabolism is of particular salience in the context of CNS disorders and injuries, as the brain has the highest lipid concentration after adipose tissue. Recent reviews on lipid signaling in CNS pathologies (1-3) and other disorders (4) are now available. This review focuses specifically on the role of phospholipase A2 (PLA2) in CNS injury and disorders. The role of ROS in conjunction with lipoxygenases will be discussed by Dr. Jae-Hong Kim in the accompanying mini-review.
PLA2 enzymes occur in multiple forms
PLA2 enzymes cleave fatty acids at the sn-2 position of glycerophospholipids, thereby yielding free fatty acids and lysophospholipids. This reaction is of particular importance when the fatty acid released from the sn-2 position is arachidonic acid (ArAc), as it can be metabolized by cyclooxygenases and lipoxygenases into a variety of bioactive eicosanoids, including prostaglandins, thromboxanes, and leukotrienes. The other PLA2 products, namely the lysophospholipids, are also biologically active and are crucial to cell signaling (5, 6) .
Nearly 22 different PLA2 enzymes have been identified in a variety of mammalian tissues (5) , and have been broadly classified into three families on the basis of their calcium requirement for catalytic activity, as calcium-dependent cytosolic (cPLA2) and secretory (sPLA2) types and calcium-independent forms (iPLA2). The PLA2 enzymes are currently systematically classified into groups on the basis of their nucleotide and amino acid sequences. The cPLA2s (α, β, γ; group IVA, IVB, and IVC) have molecular masses of 85, 114 and 61 kDa, respectively. cPLA2a requires μM Ca 2＋ concentrations for binding to lipid substrates, and preferentially hydrolyzes ArAc in the sn-2 position of phospholipids. cPLA2a is regulated via phosphorylation on Ser-505, Ser-727, and Ser-515 mediated by MAPK, MEK1, and calcium-and calmodulin-dependent kinase II, respectively, although the mechanism underlying the regulation of cPLA2a by phosphorylation remains poorly understood (7) . The sPLA2s (groups I, II, III, V, X and XII) have low molecular weight (14-19 kDa), usually require mM calcium for catalytic activity, and lack specificity for the fatty acid in the sn-2 position. In addition to their catalytic activity as phospholipases, some forms of sPLA2 can stimulate a variety of biological responses via binding to high-affinity transmembrane PLA2 receptors. The iPLA2s (group VI) have molecular masses of 84-88 kDa (8), are not selective for ArAc, and perform a crucial function in the regulation of the cell cycle through membrane phospholipid remodeling (9) . Platelet activating factor acetylhydrolases comprise PLA2 groups VII and VIII, have molecular masses of 26-45 kDa, and can also cleave short-chain oxidized fatty acids (up to nine carbons) in the sn-2 position of phosphatidylcholine (PC) or phosphatidy-http://bmbreports.org BMB reports lethanolamine. Lipoprotein-PLA2 (Lp-PLA2) is a 45 kDa group VIIA PLA2 found in the circulating blood, and is associated with apo-B100 of LDL. Elevated Lp-PLA2 level are associated with coronary heart disease, stroke, and dementia (10) . The group VII and VIII PLA2s may perform a protective function by removing the fatty acids damaged by oxidative stress. All major groups of PLA2 are present in the central nervous system (2, 11) .
cPLA 2 in cerebral ischemia

In vitro
A number of studies have demonstrated upregulation of PLA2 in a variety of cerebral ischemia models. Organotypic hippocampal slice cultures were subjected to oxygen glucose deprivation (OGD) and re-oxygenation, an in vitro model for cerebral ischemia. PLA2 activity was increased by 2-fold as compared to the controls in the hippocampal pyramidal cell layer immediately after 35 min of OGD, and the levels remained elevated at 24 h re-oxygenation. The use of PLA2 inhibitors (AACOCF3 to inhibit cPLA2 and iPLA2, BEL for iPLA2, and LY311727 for sPLA2) indicated that PLA2 activation after OGD was attributable to cPLA2. Inhibition of cPLA2 also attenuated OGD-induced neuronal death, thereby indicating that cPLA2 is involved in ischemic injury (5) . The results of recent studies have demonstrated that the release of lysosomal cathepsins induced CA1 hippocampal neuronal death via NMDAmediated calcium influx, activation of cPLA2, ArAc release, and subsequent ROS production in rat hippocampal slices subjected to OGD (12) .
Forebrain ischemia
cPLA2 gene expression was assessed in the rat brain via in situ hybridization. In the normal rat brain, faint signals were detected in hippocampal CA1-CA3 neurons and dentate granule cells. After 10 min of transient forebrain ischemia in male Wistar rats, the cPLA2 gene was expressed intensely in dentate granule cells, which remain viable after transient ischemia, at 12 and 24 h of reperfusion. Expression in CA1-CA3 was increased slightly at 6 and 12 h, but returned to control levels by 24 h (5). Increased cPLA2 immunoreactivity as compared to shams was detected in astrocytes within the CA1 region at 24 h after 30 min of 4-vessel occlusion, a time prior to histologically apparent neuronal damage. Intense labeling for cPLA2 was noted throughout the hippocampal CA1 region at 72 h after ischemia, at which time necrosis of the CA1 neurons was observed. cPLA2 was expressed selectively in activated microglia and astrocytes in regions of neurodegeneration. cPLA2 activity and protein expression were increased in the hippocampal extracts at 72 h reperfusion (5) .
Focal cerebral ischemia
24 h after permanent occlusion of the MCA, monocytes and macrophages were profoundly cPLA2 immunoreactive and were localized principally to the core of the infarct. cPLA2 immunoreactive astrocytes were detected in the penumbral region (5) .
The PLA2 inhibitor, quinacrine, ameliorated neurological deficits and reduced infarction after 2 h of transient focal cerebral ischemia (6) . The results of these studies provide evidence that PLA2 contributes to ischemic injury; however as quinacrine is a general PLA2 inhibitor, these results do not indicate which form of PLA2 was involved in the ischemic injury (6) . Indirect evidence has been provided by studies showing that the inhibition of ArAc metabolism attenuated cerebral ischemia-induced oxidative injury, bloodbrain barrier dysfunction, edema, infarction, and hippocampal neuronal death (5) . Transgenic mice deficient in cPLA2 were generated via targeted disruption of its gene. After transient focal cerebral ischemia, cPLA2 deficient mice evidenced smaller infarcts and fewer neurological deficits as compared to wild-type (5, 8) , demonstrating a role for cPLA2 in ischemic injury. We have observed no changes in total cPLA2 protein expression following transient focal cerebral ischemia (13) , a result which is consistent with those of other studies in which cPLA2 mRNA expression evidenced no changes at 3 d after ischemia (14) . In our studies, the antibody was not specific for phosphorylated cPLA2 and changes in phospho-cPLA2 would probably not have been detected (13) . Aβ-induced phospho-cPLA2 changes were apparent in AD models (15, 16) . A knockout animal may not provide us with a clear understanding of the normal function of a specific gene product, as the overall phenotype can result from primary gene loss in addition to adaptive responses occurring during development and maturation (17) . It should be noted that the C57BL/6J and 129/SV mouse strains utilized for transgenic studies harbor a naturally occurring mutation in the gene for sPLA2 IIA (5, 8) , and thus the cPLA2 knockout mice were deficient in both cPLA2 and sPLA2 IIA. Transgenic mice expressing the human sPLA2 IIA gene have been developed and are currently available from Taconic, but this mouse strain apparently has yet to be employed in stroke research to assess the function of sPLA2 IIA.
Unilateral hypoxia-ischemia
After 15 min of unilateral hypoxia-ischemia in 21-d-old male Wistar rats, cPLA2 immunoreactivity was selectively higher in the reactive glia in the hippocampal CA1 region undergoing delayed neuronal death at 3 and 7 d after injury. Immunoreactivity for cPLA2 was low in all regions of the uninjured control hemisphere (5) .
cPLA2 expression studies present the anomaly that mRNA was expressed principally in the neurons, whereas the expression of the protein was induced in the glia but was undetectable in the neurons. These differences cannot be explained by strain differences, as all of these studies used Wistar rats (5) . Recent studies have demonstrated the induction of cPLA2 by Aβ in cortical neuronal cultures, thereby indicating that neurons do express cPLA2 protein; however, the contribution from residual non-neuronal cells in these cultures cannot be ruled out entirely (15) .
sPLA 2 in cerebral ischemia
Forebrain ischemia PLA2 activities were increased significantly in the cytosolic, mi-http://bmbreports.org tochondrial, and microsomal fractions following global cerebral ischemia in gerbils, the majority of which were calcium-dependent, and measured 14 kDa, which is characteristic of sPLA2. Similar results were reported in our studies of forebrain ischemia. PLA2 activities were increased significantly in the mitochondrial and membrane fractions after 2 h of reperfusion. Maximum activity was observed at mM Ca 2＋ , thereby indicating that the membrane and mitochondrial fractions predominantly contain sPLA2 (18) . Quinacrine also attenuated CA1 neuronal death in transient forebrain ischemia in the gerbil (6) .
Group IIA sPLA2s have been studied the most due to their involvement in inflammatory processes (19, 20) . The expression of sPLA2 II mRNA in rat brain after 20 min of transient forebrain occlusion evidenced biphasic increases at 1-6 h and 7 and 20 d post-ischemia (5 and references cited therein).
Focal cerebral ischemia
sPLA2 IIA mRNA demonstrated biphasic increases in expression at 30 min of reperfusion after 60 min of focal cerebral ischemia and from 12 h to 3 d, which declined to sham levels by 7 d and then again increased at 14 d. The increase in sPLA2 IIA mRNA occurred principally in the ischemic cortex, whereas the increases at 1 and 3 d were observed principally in the penumbra. The levels of sPLA2 IIA protein were expressed principally in the penumbra at 3 d post-ischemia and the protein was localized in the GFAP-positive astrocytes but not in the microglia (14) .
We also noted a 4-fold increase in sPLA2 IIA mRNA within the ipsilateral cortex as compared to the contralateral cortex after 1 h of middle cerebral artery occlusion (MCAO) and 24 h of reperfusion in spontaneously hypertensive rats (13) . sPLA2 protein expression was increased significantly in the ipsilateral cortex over 7 d of reperfusion after 1 h of MCAO (21) .
In cases of permanent MCAO, PLA2 activity reached a maximum at 8 h and was increased by 2-fold as compared to the activity seen in the contralateral cortex. The sPLA2 inhibitor, indoxam, significantly reduced infarct volume. In vitro, sPLA2 IIA induced complete neuronal death in cultured rat cortical neurons, but exerted no detectable effect on the survival of astrocytes (5 and references cited therein).
PLA2 in spinal cord injury (SCI)
The first event after SCI is the depolarization and opening of voltage-dependent ion channels, and the consequent massive release of neurotransmitters, including glutamate. The accumulation of intracellular calcium initiates mitochondrial dysfunction, and the activation of nitric oxide synthase (NOS) and PLA2. The resultant generation of free radicals (comprised of different species including reactive nitrogen species (RNS), ROS and other radicals) and subsequent lipid peroxidation is thought to constitute a major pathway of secondary injury in SCI (22) . PLA2 activity and cPLA2 expression were increased significantly after SCI; cPLA2 expression was confined to neurons and oligodendrocytes. Mepacrine, a PLA2 inhibitor, attenuated spinal neuronal death in vitro and PLA2-induced demyelination in vivo (22) .
PLA 2 in neurodegenerative diseases
The mRNA expression of pro-inflammatory sPLA2 IIA was upregulated in Alzheimer's Disease (AD) brains as compared to non-dementia elderly brains. sPLA2 IIA immunoreactive astrocytes in the AD hippocampus were associated with Aβ plaques (23) . Aβ and NMDA induced cPLA2 phosphorylation, and ArAc release via the activation of NADPH oxidase, ROS generation, and ERK1/2 activation in cortical neuronal cultures (15, 24) . Aβ induced mitochondrial dysfunction through iPLA2 and cPLA2 in cultured cortical astrocytes (16) .
Free radical generation and lipid peroxidation perform a significant function in Parkinson's Disease (PD). It is believed that one of the factors responsible for this is phospholipase activation in the substantia nigra, a notion that is supported by the fact that cPLA2 deficient mice are resistant to 1-methyl-4-phenyl-1,2,3,6-tetrohydropyridine (MPTP) induced neurotoxicity (6), an animal model for PD.
Experimental autoimmune encephalomyelitis (EAE)
can be induced in animals via immunization against myelin antigens (25) and is an animal model for multiple sclerosis (MS), owing to similarities in its histopathology and clinical course. Recent studies have demonstrated that cPLA2 performs a pivotal function in EAE (25, 26) . cPLA2, which can be induced by the cytokine tumor necrosis factor-α (TNF-α) (27) , was expressed abundantly in EAE lesions. The blockage of cPLA2 resulted in a marked reduction in both the onset and progression of the disease (25) , thereby indicating that cPLA2 performs a significant function in both the induction and effector phases of EAE. A second study demonstrated that cPLA2 null mice were resistant to EAE (26) . The treatment of EAE rats with the nonapeptide sPLA2 inhibitor, CHEC-9, significantly attenuated sPLA2 activity, EAE symptoms, and ED-1 positive microglia/macrophages (28) . Recently, MS patients were found to have elevated levels of sPLA2 activity in the urine (28) . These studies demonstrate that both cPLA2 and sPLA2 inhibition may prove to be effective treatment options for MS.
Reactive oxygen species (ROS) contribute to stroke injury
ROS, including hydrogen peroxide (H2O2) and the superoxide radical (O2
•−
) are generated by a number of cellular oxidative metabolic processes, such as xanthine oxidase, NADPH oxidase, the metabolism of ArAc by cyclooxygenases (COX) and lipoxygenases (LOX) (29, 30) , and the mitochondrial respiratory chain. Cardiolipin is an exclusive inner mitochondrial phospholipid which is essential for mitochondrial electron transport (31) . The hydrolysis of cardiolipin by mitochondrial sPLA2 could disrupt the mitochondrial respiratory chain, thereby resulting in increased ROS generation. ROS can also be formed non-enzymatically, for example via the autoxidation of catecholamines (18) Sources of ROS and the involvement of PLA2 are summarized in Fig. 1 . Reports in the recent literature suggest that COX-2 does not directly generate ROS during ArAc oxidative metabolism, but does form free radicals (i.e., tyrosyl radicals on the protein and carbon-centered radicals on ArAc) (32) . ROS production was elevated in a stroke model, but was not attenuated in COX-2 deficient mice, nor by the COX-2 inhibitor NS398 (33). Mice deficient in the nox2 subunit of O2
•− -producing NADPH oxidase (33) evidenced reduced ROS generation, thereby implicating NADPH oxidase as a significant source of ROS in the stroke model. Although there have been many reports in the relevant literature concerning ROS production by COX, this may be attributable to secondary ROS generation induced by a variety of eicosanoids. However, in the studies cited above (33), COX-2 inhibition or knockout would be expected to attenuate any secondary ROS production attributable to COX-2 metabolites. This apparent incongruity may be due to the specific time points selected. The studies of Kunz, et al. demonstrated increased ROS generation over 2 h to 3 days. ROS production following the inhibition of COX-2 by NS398 or in COX-2 null mice was determined at 2 h and 3 days, which does not preclude the possibility of COX-2 dependent ROS generation during the intermediate 2-48 h reperfusion times. NS398 did reduce ROS generation in the hippocampal slices subjected to OGD as measured by DHE fluorescence, thus leaving open the notion that COX-2 may contribute, at least indirectly, to ROS generation (12) .
Endogenous defenses that detoxify ROS include enzymatic systems such as superoxide dismutase (SOD), catalase, and glutathione peroxidase (GSH-Px), and non-enzymatic antioxidants including ascorbic acid, vitamin E, β-carotene, and glutathione (GSH) (5). Neurons may be particularly vulnerable to free radical damage, as they harbor low levels of GSH (34) . While ROS have been proposed to perform crucial functions in the coordination and regulation of a number of cellular signaling pathways (redox signaling), oxidative stress results when ROS formation exceeds the capacity of anti-oxidant defense systems (35) . The results of studies utilizing transgenic mouse models have provided evidence suggesting that ROS contribute to ischemic brain injury. Mice overexpressing either SOD1 or GSH-Px-1 evidenced significantly smaller infarcts than were seen in the wild-type counterparts after focal cerebral ischemia. Conversely, ischemic injury was increased in SOD1-deficient mice (35) .
ROS and RNS initiate lipid peroxidation
The highly reactive hydroxyl radical (•OH) is formed from H2O2 in the presence of divalent metal ions, particularly Fe 
Lipid peroxidation products can alter cellular function
The peroxidation of lipids can disrupt the organization of the membrane, inducing changes in fluidity and permeability, inhibition of metabolic processes, and alterations in ion transport (37) . Damage to mitochondria induced by lipid peroxidation can result in further ROS generation. In the presence of oxygen radicals, the double bonds of unsaturated fatty acids of phospholipids can become oxidized. The scission of the oxidized polyunsaturated fatty acids results in the formation of phospholipid aldehydes including oxidized phosphatidylcholine (OxPC), and aldehyde cleavage fragments including malondialdehyde (MDA), 4-hydroxynonenal (HNE), and acrolein (38, 39) . These aldehydes, in turn, bind covalently to proteins and alter their functions. Among all α,β-unsaturated aldehydes, acrolein is by far the strongest electrophile and evidence the highest level of reactivity with proteins. Overproduction of lipid peroxides and al-http://bmbreports.org dehyde products can induce the depletion of GSH via detoxification by GSH-Px and glutathione S-transferase (18) .
The presence of OxPC on the apoptotic cell surface has been detected using EO6 monoclonal antibodies that bind exclusively to OxPC and OxPC-protein adducts (40) . The oxidation of PC to OxPC on apoptotic cells may enhance pro-inflammatory signals (41, 42) . The existence of OxPC has been demonstrated in the brains of multiple sclerosis patients using EO6 monoclonal antibodies (40) . Although multiple sclerosis (a brain disorder) and stroke (brain injury) have specific differences, inflammatory response and ROS production are common factors between the two.
Lipid peroxidation in cerebral ischemia
Global cerebral ischemia
Transient forebrain ischemia in the gerbil (which lacks a Circle of Willis and thus collateral blood flow) is characterized by delayed hippocampal CA1 neuronal death. Neurodegeneration is evident by 3 d reperfusion and culminates in neuronal death by 6 d (43). Five min of forebrain ischemia and 6 h of reperfusion in the gerbil resulted in significantly increased levels of MDA, HNE, and lipid hydroperoxides in the cortex, striatum, and hippocampus and thus preceded the onset of neuronal death (44). These increases persisted over 4 d of reperfusion in the ischemia-vulnerable hippocampus.
In another study (39 and references cited therein) involving 3 min of global cerebral ischemia, a transient increase in nuclear HNE immunoreactivity was noted in the hippocampal CA1 neurons with little or no reactivity in the cytosol. By way of contrast, cytoplasmic immunoreactivity increased markedly from 8 h to 7 d of reperfusion. At 7 d, HNE immunoreactivity was noted within the reactive astrocytes in the CA1 region. Similar results were noted in our studies in 10 min forebrain ischemia and 24 h of reperfusion in the gerbil. Immunohistochemical studies have demonstrated localization of HNE in the ischemia-susceptible hippocampal CA1 region (5) . HNE immunoreactivity was strongest in the nuclei, with significant labeling also detected in the cytoplasm. Little or no HNE immunoreactivity was noted in the shams.
Lipid peroxidation was evaluated via thiobarbituric acid assays in rat brains after 30 min of forebrain ischemia and up to 72 h of reperfusion. Lipid peroxide levels were unchanged during ischemia and 1 h reperfusion but increased between 8 and 72 h of recirculation in the ischemia-vulnerable hippocampus, with the greatest increase observed at 48 h (5 and references cited therein).
HNE immunoreactivity was assessed post-mortem in a group of patients who had experienced global cerebral ischemic (cardio-respiratory) attacks and had subsequently died. We noted a substantial increase in the number of HNE-positive neurons and glia in the hippocampi of the ischemic group as compared to the age-and sex-matched controls (45) .
Focal cerebral ischemia
Relative generation of OxPC in the ischemic hemisphere vs contralateral region was assessed via Western blot assay following transient focal cerebral ischemia and 1 day reperfusion. Our studies demonstrated an increase in OxPC-modified protein (∼15 kDa) in the ischemic cortex as compared to the contralateral cortex (Fig. 2) . The identity of the modified 15-kDa protein currently remains unknown (40) .
The proteasome is a large 700 kDa complex which performs the majority of protein degradation, and is responsible for the removal of most oxidized, aggregated, or damaged proteins. The activity of the proteasome complex was shown to decrease after transient focal cerebral ischemia in mice, without any corresponding reduction in the protein expression of the proteasome subunits. Levels of HNE-modified proteasome complex subunits increased at as early as 1 h of reperfusion, thereby suggesting that the loss of proteasome activity was attributable to the modification by HNE. GSH-Px-deficient mice evidenced further increased levels of HNE-modified proteasome subunits (46) .
Using an antibody against HNE-modified proteins, no HNE immunoreactivity was detected at 1 h, but was detectable in neurons within the infarcted zone at 3 h and in the boundary between the infarcted and non-infarcted zones over 6-48 h of reperfusion following 3 h of focal cerebral ischemia in the rats (39 and references cited therein). Bcl-2 expression attenuates ischemic injury. In transient forebrain ischemia, the hippocampal CA1 neurons that are destined to die stop generating Bcl-2 protein (47), and it is conceivable that increased levels of HNE-modified proteins are attributable, at least in part, to this lack of Bcl-2 expression.
In permanent focal cerebral ischemia in the rat, HNE immunoreactivity increased in the ipsilateral hemisphere 4 h after the induction of MCAO. HNE immunoreactivity extended beyond the region of ischemic damage, which suggests that http://bmbreports.org BMB reports
CNS pathology Role of PLA2
Alzheimer disease Upregulation of PLA2, increased lipid peroxidation (6, 50, 54) . sPLA2 IIA expression increased in AD rains (23) . Aβ induced mitochondrial dysfunction through iPLA2 and cPLA2. Aβ induced cPLA2 phosphorylation via NADPH oxidase and ROS production (15, 16 ).
Parkinson's diseases cPLA2knock out mice showed protection against MPTP toxicity (6).
Multiple sclerosis-experimental autoimmune encephalomyelitis (MS-EAE) cPLA2 is highly expressed in EAE (6). cPLA2-deficient mice are resistant to EAE (26) . sPLA2 activity increased and inhibition by CHEC-9 blocks inflammation (28).
Wallerian degeneration PLA2 plays an important role in myelin breakdown and phagocytosis. PLA2 expressed during the early stage of Wallerian degeneration hydrolyzes PC in myelin to LPC and ArAc (51) . LPC can aggravate the inflammatory responses that can further up-regulate cPLA2 in a positive feedback manner.
Transient focal cerebral ischemia (Stroke) Activation of PLA2 and increased sPLA2 expression (5, 13, 14) . cPLA2 knockout mice showed protection (5 and references cited therein). CDP-choline attenuated sPLA2 (13) . PLA2 inhibitor quinacrine reduced the infarction size (6).
Spinal Cord Injury cPLA2 expression, PLA2 activity were increased (22) ; Mepacrine reduced PLA2-induced neuronal death. The studies did not directly assess the role of endogenous PLA2 in neuronal injury after SCI. Major part of the studies conducted injecting PLA2 or mellitin to spinal cord of normal rats and showed increases in TNF-α, IL-1β and HNE. HNE-modified proteins accumulated in the tissues prior to the development of infarction (5 and references cited therein). In another study, MDA and conjugated diene levels were elevated significantly in the ipsilateral cortex as compared to the contralateral cortex after 60 min of permanent MCAO (5). EPC-K1 (a phosphodiester of vitamin C and E that inhibits PLA2 activity and lipid peroxidation) reduced spatial learning deficits after 20 min of transient global ischemia (4-vessel occlusion) in male Wistar rats. In another study, EPC-K1 induced significant reductions in both cerebral lipid peroxidation and infarcts in transient focal cerebral ischemia, thereby indicating the contribution of lipid peroxidation to ischemic brain injury (5) .
To date, studies concerning aldehyde products in the ischemic brain have focused on HNE and have demonstrated increased lipid peroxidation in several cerebral ischemia models. Recent studies have suggested that acrolein may function as a novel biochemical marker for the diagnosis of stroke; however, acrolein formation was attributed to the polyamine oxidase pathway (48, 49) .
Lipid peroxidation in neurodegenerative diseases
A number of studies have demonstrated increased lipid peroxidation in cases of AD, thereby supporting the notion that oxidative damage performs a relevant role in AD (50) . Recent studies demonstrated increased levels of HNE and acrolein in the brain tissue from patients affected by mild cognitive disorder and early AD, thereby indicating that lipid peroxidation occurs early in the pathogenesis of AD (50) . ROS may also perform a function in amyloid deposition in AD, as oxidizing conditions induce protein cross-linking and the aggregation of Aβ peptides, and also contribute to the aggregation of tau protein (2) .
Multiple sclerosis (MS) is an inflammatory demyelinating autoimmune disease which affects the CNS, but its underlying cause remains elusive. In MS, the immune system attacks the myelin sheath of nerve cell fibers in the brain and spinal cord. Thiobarbituric acid reactive substances and F2-isoprostane levels have been shown to be elevated in the CSF of MS patients, and HNE has been associated with MS lesions, which indicates that lipid peroxidation also occurs in cases of MS (1) .
Wallerian/anterograde degeneration occurs when a nerve fiber is cut or crushed and the portion distal to the injury (i.e. the part of the axon separated from the neuron's cell nucleus) degenerates, a process in which PLA2 plays an important role, namely in myelin breakdown and phagocytosis (51) . Wallerian degeneration occurs after axonal injury in both the peripheral nervous system (PNS) and the CNS. The axonal degeneration is followed by the degradation of the myelin sheath and infiltration by macrophages. The macrophages, accompanied by Schwann cells, function to clear the debris from the degeneration. The PNS is much faster and more efficient at clearing myelin debris than is the CNS, and Schwann cells are the primary factor in this difference. PLA2 expressed during the early stage of Wallerian degeneration hydrolyzes PC in the myelin to LPC and ArAc. LPC can induce further myelin breakdown while eicosanoids derived from ArAc stimulate inflammatory responses.
Increased lipid peroxidation has been reported in conjunction with Parkinson's Disease, Huntington's Disease, and amyotrophic lateral sclerosis, but the involvement of PLA2 has yet to be demonstrated (1).
Conclusions and future perspectives
The findings thus far published reveal increases in cPLA2 and sPLA2 in cases of stroke (5) and neurodegenerative diseases (Table 1) . Gene knockout studies have demonstrated the role of cPLA2 (17) in ischemic injury, MS-EAE (26) , and Parkinson's disorder (6) . The high level of cPLA2 expression in myelin disorders including MS-EAE (25) and Wallerian degeneration (51) , and resistance against MPTP-induced Parkinsonism in cPLA2 null mice suggests the potential for cPLA2 pharmacological interventions. While iPLA2s perform a crucial role in the regulation of the cell cycle by membrane phospholipid remodeling (9) , their role in CNS pathology remains to be definitively established. A neuronal sPLA2 receptor has been identified and is abundantly expressed in the brain (52) , but its physiological functions, ligand interactions, and possible function in neurodegeneration have yet to be elucidated. PLA2 activating protein, which greatly stimulates sPLA2 activity and is expressed in the brain, is another factor that remains to be explored sufficiently (5) . A number of group IIA sPLA2 inhibitors have already been developed (53) , but most of these have yet to be tested in the context of CNS pathologies.
